ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2025
Single-Cell RNA Sequencing Highlights a Contribution of Human Amniotic Mesenchymal Stem Cells-Derived Exosomes to Androgenetic Alopecia.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- hUC-MSC-exosomes deliver Let-7b/7f-5p to dermal papilla cells for a multi-target synergistic treatment of androgenetic alopecia.Journal of nanobiotechnology · 2026Article
- Extracellular Vesicles for Androgenetic Alopecia: Current Evidence, Mechanisms, and Clinical Prospects.International journal of nanomedicine · 2026Review
- Amelioration of psoriasis-like skin lesions by human amniotic mesenchymal stem cells: insights from multiomics profiling in mice.Frontiers in immunology · 2026Article
- Promises and Pitfalls of Regenerative Therapies for Androgenetic Alopecia: Platelet-Rich Plasma, Photobiomodulation, Stem Cells, and Exosomes.Medical sciences (Basel, Switzerland) · 2025Review
- Single-Cell RNA Sequencing Highlights a Contribution of Human Amniotic Mesenchymal Stem Cells-Derived Exosomes to Androgenetic Alopecia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Androgenetic alopecia (AGA) is a prevalent disorder caused by dihydrotestosterone (DHT), characterized by hair follicle (HF) miniaturization and hair sparsity. Human amniotic mesenchymal stem cells (hAMSC) have been reported as promising stem cells for clinical therapy due to their no tumorigenicity, low immunogenicity, no ethical concerns, potent proliferative potential, and tissue repair. At present, the effects and underlying mechanism of exosomes derived from hAMSC (hAMSC-exo) on AGA are still not explored. Here, we reported that hAMSC-exo accelerated hair growth in AGA mice. Then, single-cell RNA sequencing was performed to analyze the cellular landscape of mouse dorsal skin, identifying 15 cell types and determining the differentiation trajectory of HF during hAMSC-exo-induced hair growth. It was found that hAMSC-exo strengthened crosstalk between cycling HF cells and niche-resident DPC, providing critical signaling for orchestrating hair follicle stem cells (HFSC) differentiation. Focusing on DPC, we further demonstrated that hAMSC-exo alleviated DHT-induced mitochondrial dysfunction and exerted protection against DHT-induced DPC damage via Wnt/β-catenin signaling, which may reset the HFSC niche to a favorable environment for HF regeneration. These results revealed the protective effect and molecular mechanisms of hAMSC-exo against hair loss at the single-cell level and provided a novel therapy combating AGA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.